However, pan‐HER TKIs inhibit both Her2 and EGFR, thus suppressing the Her2‐HSF1‐mutP53 interaction and leading to destabilization of the mutP53 protein in cancer cells.7, 24. The gene discussed is ERBB2; the disease is cancer.